TREATMENT OF HBV INFECTION Russian patent published in 2017 - IPC C12N15/113 A61K48/00 A61P31/20 

FIELD: pharmacology.

SUBSTANCE: invention relate to the means for directed DNA of RNA interference (ddRNAi) (versions) for inhibiting the expressions of RNA-dependent DNA polymerase of hepatitis B virus (HBV), an expression cassette for expressing the means for ddRNAi, an expression vector for ddRNAi, a pharmaceutical composition comprising means for ddRNAi and their use for treatment of the infections caused by hepatitis B, of individuals. The characterized means comprises, in the direction from 5' to 3': the first effector sequence with a length of 18-22 nucleotide, the first effector complementary sequence, the second effector sequence with a length of 18-22 nucleotides, and the second effector complementary sequence; the third effector sequence with a length of 18-22 nucleotides; and the third effector complementary sequence, where each effector sequence is, substantially, complementary to the section of the predicted gene transcript of RNA-dependent DNA polymerase. Several effectors may target the same HBV gene section, different (possibly overlapping) sections of the same gene, and/or different HBV genes.

EFFECT: possibility of using the invention for targeting the HBV expression in the cells for the treatment of HBV infection.

16 cl, 10 dwg, 6 tbl, 9 ex